Hidoc Dr | Medical Learning App for Doctors

Today's Updates

Hyponatremia Risk Varies Among Second-Gen Antipsychotics

Published Date: 22 Aug 2026

Aripiprazole is associated with a lower risk for hyponatremia compared with olanzapine in patients treated with second-generation antipsychotics, a new cohort study shows.

HCT Survival Outcomes Improving in Relapsed Hodgkin Lymphoma

Published Date: 22 Aug 2026

Researchers evaluate changes in post-transplantation outcomes among patients with relapsed or refractory Hodgkin lymphoma from 2010 to 2022.

How Much of a Cancer Drug Is Too Much?

Published Date: 22 Aug 2026

In a recent KFF survey, 43% of US adults said they had skipped their medication in the past year because of cost.

Knowledge Hub

Oncology

Patient-Specific Tumor Resection Cavities With Biofabricated Reconstruction Materials

Comprehensive review of patient-specific biofabricated reconstruction materials for tumor resection cavities, focusing on clinical evidence and guideline-based practice.

Oncology

Case-Based Learning: Reasoning Through New Functional Changes During Long-Term Cancer Survivorship

Comprehensive review on reasoning through new functional changes during long-term cancer survivorship, with evidence-based clinical insights.

Oncology

Clinical Pharmacology of Drug Exposure During Long-Term Cancer Survivorship

Comprehensive review of drug exposure and clinical pharmacology in long-term cancer survivors.

Oncology

Drug Safety Surveillance of Long-Term Medication Effects in Cancer Survivorship

A comprehensive review of drug safety surveillance for long-term medication effects in cancer survivorship.

Oncology

KOL Videos

Hidoc Dr| Hidoc- US| Hidoc - Doctor Netwoking Platform| Educational resource for HCPs

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

Your one-stop Solution for MEDICAL LEARNING & UPDATES

Hyponatremia Risk Varies Among Second-Gen Antipsychotics

HCT Survival Outcomes Improving in Relapsed Hodgkin Lymphoma

How Much of a Cancer Drug Is Too Much?

Knowledge Hub

Patient-Specific Tumor Resection Cavities With Biofabricated Reconstruction Materials

Case-Based Learning: Reasoning Through New Functional Changes During Long-Term Cancer Survivorship

Clinical Pharmacology of Drug Exposure During Long-Term Cancer Survivorship

Drug Safety Surveillance of Long-Term Medication Effects in Cancer Survivorship

Emerging Therapies Using Tumor-Activated Prodrug Systems for Selective Cancer Cell Killing

Emerging Therapies Using Targeted Antibody–Drug Conjugates Against Previously Difficult Tumor Targets

Emerging Therapies Using Combination Radiopharmaceutical Platforms for Sequential Tumor Targeting

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Page Views

Your one-stop Solution for MEDICAL LEARNING & UPDATES

Hyponatremia Risk Varies Among Second-Gen Antipsychotics

HCT Survival Outcomes Improving in Relapsed Hodgkin Lymphoma

How Much of a Cancer Drug Is Too Much?

Knowledge Hub

Patient-Specific Tumor Resection Cavities With Biofabricated Reconstruction Materials

Case-Based Learning: Reasoning Through New Functional Changes During Long-Term Cancer Survivorship

Clinical Pharmacology of Drug Exposure During Long-Term Cancer Survivorship

Drug Safety Surveillance of Long-Term Medication Effects in Cancer Survivorship

Emerging Therapies Using Tumor-Activated Prodrug Systems for Selective Cancer Cell Killing

Emerging Therapies Using Targeted Antibody–Drug Conjugates Against Previously Difficult Tumor Targets

Emerging Therapies Using Combination Radiopharmaceutical Platforms for Sequential Tumor Targeting

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Verification

Welcome to Hidoc Dr.

Page Views